secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001193125-23-169513
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences shareholders elect three Class II directors and approve say-on-pay
--------------------------------------------------------------------------------

- All three director nominees (Jack Ball, Vera Imper, Ming Yan) elected with 55.9M–56.9M votes for; broker non-votes 25.6M.
- Advisory vote on 2022 executive compensation passed with 57.4M for, 1.4M against, 0.8M abstentions.
- Advisory vote on frequency of say-on-pay: one-year option received 58.6M votes; two- and three-year options negligible.
- Ratification of Deloitte & Touche as auditor for FY2023 approved with 84.9M for, 11k against.
- Approximately 63% of outstanding shares (85.2M of 135.7M) represented at the 2023 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/d483871d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-169513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer